Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorFar Eastern Memorial Hospital

About this trial

Hypertrophic cardiomyopathy (HCM) is hallmarked by the presence of left ventricular hypertrophy (LVH) and may present various symptoms including arrhythmia and heart failure. Mutations in the genes related to sarcomeric proteins and metabolic disorders are known causes of HCM. However, it remains required to further explore the prevalence of HCM in the context of Taiwanese' genetic background. Additionally, certain rare diseases that affect the heart, including Fabry disease, cardiac amyloidosis, may present LVH, which makes precise diagnosis among HCM and these diseases more challenging. In this TSOC multi-center registry, we aim to systematically evaluate the clinical, genetic, biochemical features,prevalence, and possible natural course of HCM and relevant rare diseases such as Fabry disease in Taiwan. In the meanwhile, we may also generate the specific "red-flag" signs of Fabry disease in Taiwan.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

maximal interventricular septal (IVST) and/or posterior wall thickness (PWT) ≥13 mm,

apical wall thickness ≥15 mm or a ratio of apical to basal LV wall thickness of ≥ 1.3 at end-diastole, OR

maximal LV wall thickness ≥ 15mm of ANY OTHER PART

Male and female adult age ≥ 20 year-old

Disqualifiers

Patients refuse or unable to give informed consent

Patients unlikely to comply with the protocol or unable to understand the nature and possible consequences of the program

Co-arctation of the aorta, severe aortic stenosis, or severe LV pressure overload

Athletic heart

Trial population

Presence of left ventricular hypertrophy

Trial design

Design model

Case-only

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Death

Death

Time frame
1 year

Secondary outcomes

1

CV death

CV death

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.